We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Teva Pharmaceutical Industries may buy Merck KGaA's generic drugs division for $5.3 billion, reports the Israeli business newspaper Globes, which cited German news reports.
The production, sale and distribution of Pravachol and generic pravastatin sodium by Bristol-Myers Squibb (BMS) and Watson Pharmaceuticals are being challenged in U.S. federal court.
Belgian drugmaker Galapagos has announced that its service division, BioFocus DPI, has expanded and extended its longstanding drug discovery collaboration with Amgen through 2007 and 2008.
MedImmune has announced it intends to develop a monoclonal antibody (MAb) targeting pathways within the CD28 receptor family for treatment of certain inflammatory diseases under a recently signed license agreement with Japan Tobacco (JT).
U.S.-based biotechnology firm Exelixis announced it has entered into an agreement with Genentech for the worldwide co-development of XL518, a small-molecule inhibitor of MEK, for treating cancer.
South Africa's new drug price regulations, which were supposed to go into effect this week, have been put on hold in wake of a long-running legal battle between pharmacies and the government, reports the Johannesburg-based Business Day.
Danish drugmaker ALK-Abello has signed an agreement with Schering-Plough to develop and commercialize its tablet-based allergy immunotherapies in several countries, including the U.S.
Zimbabwe's government will this year triple the number of people enrolled in the public antiretroviral (ARV) drug program, increasing the number to 160,000 from roughly 50,000 last year, The Herald, the country's government-owned newspaper, has reported.
A Canadian court ruling that dismissed an appeal request by Apotex
signals another defeat for the generic drugmaker in its efforts to market generic clopidogrel bisulfate.